MARKET

EBS

EBS

Emergent Bio
NYSE

Real-time Quotes | Nasdaq Last Sale

63.51
-1.97
-3.01%
After Hours: 64.00 +0.49 +0.77% 19:54 06/11 EDT
OPEN
65.51
PREV CLOSE
65.48
HIGH
66.12
LOW
62.72
VOLUME
829.60K
TURNOVER
--
52 WEEK HIGH
137.61
52 WEEK LOW
55.07
MARKET CAP
3.40B
P/E (TTM)
8.89
1D
5D
1M
3M
1Y
5Y
S.Africa to analyse J&J vaccines made at U.S. plant halted over error
reuters.com · 1d ago
Emergent BioSolutions Saus Two Batches Of COVID-19 Vaccine Manufactured By Co. Were Determined Suitable For Use By FDA
 Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batches of COVID-19 vaccine manufactured by Emergent BioSolutions at its Baltimore Bayview facility were determined to be suitable for use by the U.S.
Benzinga · 2d ago
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson's Emergency Use Authorization
-- Emergent continues to work with the FDA to address identified observations at Bayview facility in order to release additional batches and resume production
GlobeNewswire · 2d ago
Millions of J&J Doses Cleared for Use, Many Remain in Limbo
Bloomberg · 2d ago
FDA Authorizes 10M JNJ COVID-19 Vaccine Doses, Asks To Discard 60M From Emergent Plant: NYT
Benzinga · 2d ago
UPDATE 1-U.S. FDA asks J&J to discard 60 mln vaccine doses made at Baltimore plant -Times
reuters.com · 2d ago
UPDATE 3-U.S. FDA asks J&J to discard millions of COVID-19 vaccine doses
reuters.com · 2d ago
JNJ will need to trash 60M COVID doses from Emergent plant but can distribute 10M (updated)
The FDA has determined that 60M doses of Johnson & Johnson's (JNJ) COVID-19 vaccine produced at a troubled Emergent BioSolutions (EBS) plant must be discarded because of possible contamination, The
Seekingalpha · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EBS. Analyze the recent business situations of Emergent Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EBS stock price target is 91.14 with a high estimate of 120.00 and a low estimate of 64.00.
EPS
Institutional Holdings
Institutions: 442
Institutional Holdings: 49.97M
% Owned: 93.26%
Shares Outstanding: 53.59M
TypeInstitutionsShares
Increased
119
4.13M
New
44
367.17K
Decreased
137
2.88M
Sold Out
47
516.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Executive Director
Fuad El-Hibri
Chairman/Director
Fuad El-Hibri El-Hibri
President/Chief Executive Officer/Director
Robert Kramer
Chief Financial Officer/Executive Vice President/Treasurer
Richard Lindahl
Chief Human Resource Officer/Executive Vice President
Katherine Strei
Executive Vice President/General Counsel/Secretary
Atul Saran
Executive Vice President
Adam Havey
Executive Vice President
Sean Kirk
Executive Vice President
Karen Smith
Lead Director/Independent Director
Ronald Richard
Director
Marvin White
Independent Director
Zsolt Harsanyi
Independent Director
Jerome Hauer
Independent Director
George Joulwan
Independent Director
Louis Sullivan
Independent Director
Kathryn Zoon
No Data
About EBS
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Webull offers kinds of Emergent Biosolutions Inc stock information, including NYSE:EBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EBS stock methods without spending real money on the virtual paper trading platform.